Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 24, 2020

UK authorises 30 minute self-test kit to detect asymptomatic Covid-19 cases

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued exceptional use authorisation for an NHS Test and Trace Covid-19 Self-Test device.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued exceptional use authorisation for an NHS Test and Trace Covid-19 Self-Test device.

The Department of Health and Social Care was granted authorisation to use the rapid test kit for detecting infection in asymptomatic people.

This is an antigen lateral flow test (antigen LFT) which is capable of delivering results in 30 minutes.

The device can be used to detect new Covid-19 cases in those individuals who do not have symptoms.

Individuals with no prior knowledge of testing can use a self-test device in their own home or another community setting.

In a separate development, Public Health England (PHE) Porton Down laboratory scientists have conducted a rapid evaluation to test whether the new VUI 202012/01 variant can be identified by lateral flow devices (LFDs) currently used in the UK.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The evaluation was carried out with clinical and lab-grown samples containing the variant and tested five LFDs.

Each device is either in use as part of mass testing or in the final stages of validation at PHE and could detect samples with the new variant.

One of the new tools being used for detecting Covid-19, LFDs can provide results rapidly in under 30 minutes.

They can be used to detect people who have high levels of Covid-19 virus but are not having symptoms and would not otherwise be coming forward to get tested.

Furthermore, as the new variant affects the spike protein on the virus surface, the LFDs work by detecting the nucleocapsid protein located inside the virus which is less likely to be affected.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU